Adarigiline

Overview of the drug Adarigiline

Adarigiline
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Adarigiline is a monoamine oxidase inhibitor (MAOI) that has been investigated for its potential use in the treatment of neurodegenerative disorders, particularly Parkinson's disease. It is a selective and irreversible inhibitor of the enzyme monoamine oxidase B (MAO-B), which is involved in the breakdown of dopamine in the brain.

Mechanism of Action

Adarigiline functions by inhibiting the activity of MAO-B, an enzyme that degrades dopamine. By preventing the breakdown of dopamine, adarigiline increases the availability of this neurotransmitter in the central nervous system. This action is particularly beneficial in conditions like Parkinson's disease, where dopamine levels are critically low.

Pharmacokinetics

Adarigiline is administered orally and is well absorbed from the gastrointestinal tract. It undergoes extensive metabolism in the liver, primarily through the action of cytochrome P450 enzymes. The metabolites are excreted via the kidneys.

Clinical Applications

Adarigiline has been primarily studied for its potential use in treating Parkinson's disease. By increasing dopamine levels, it may help alleviate symptoms such as bradykinesia, rigidity, and tremor. However, as of the latest updates, adarigiline has not been approved for clinical use and remains an investigational drug.

Side Effects

The side effects of adarigiline are similar to those of other MAO-B inhibitors and may include nausea, dizziness, insomnia, and headache. Due to its mechanism of action, there is also a risk of hypertensive crisis if taken with tyramine-rich foods or certain medications.

Research and Development

Research on adarigiline has focused on its neuroprotective properties, with studies suggesting it may help slow the progression of neurodegenerative diseases. However, further clinical trials are necessary to fully understand its efficacy and safety profile.

Related Pages

• Monoamine oxidase inhibitor
• Parkinson's disease
• Dopamine
• Neurodegenerative disorder